Every night, many people with obstructive sleep apnea strap a bulky mask to their face, listen to the hum of a machine, and hope they can fall asleep despite air pressure pushing into their airways. This is the nightly reality of CPAP therapy. For many, it’s a reality they eventually abandon.
A familiar name in the weight-loss world has entered this space. On December 20, 2024, the FDA approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea in adults with obesity [FDA]. It is meant to be used with a reduced-calorie diet and increased physical activity. The FDA described it as the first drug treatment option for certain people with obstructive sleep apnea [FDA]. That makes it a medicine option for a condition long managed with devices and surgery.
What the Fast Track Designation Means
When people hear “fast track” in the context of drug approval, a natural concern surfaces: does faster mean less safe?
The designations affect the pace and process of a review.
The FDA said Zepbound received Fast Track, Priority Review, and Breakthrough Therapy designations for this indication [FDA]. Fast Track allows more frequent communication with the FDA and lets a company submit finished sections of an application before the whole package is ready [FDA Fast Track]. Priority Review sets a review goal of 6 months instead of 10, and the FDA states that it does not alter the scientific and medical standard for approval [FDA Priority Review].
The approval rested on two randomized, double-blind, placebo-controlled trials that enrolled 469 adults without type 2 diabetes. One trial enrolled people who were not using positive airway pressure (PAP) therapy and the other enrolled people who were. Participants received 10 or 15 mg of tirzepatide weekly or a placebo for 52 weeks [FDA]. Eli Lilly funded the trials, which are known as SURMOUNT-OSA and were published in the New England Journal of Medicine [NEJM].
The main measure was the apnea-hypopnea index (AHI), which counts how often breathing is disrupted per hour of sleep. At the start, participants averaged about 50 events per hour. By week 52 the AHI had fallen by 25.3 events per hour on tirzepatide and 5.3 on placebo in the first trial, and by 29.3 versus 5.5 in the second [NEJM].
Sleep Apnea’s Hidden Weight Connection
Here’s something that surprises many people: obstructive sleep apnea isn’t just about how you sleep.
It is closely connected to how much you weigh.
Sleep apnea can affect anyone, but the FDA notes it is more common in people who have overweight or obesity [FDA]. The mechanism is physical. Excess tissue around the neck and throat can narrow the airway and make it more likely to collapse during sleep. Each time it does, breathing stops briefly, oxygen levels drop, and the body jolts itself awake.
Weight change tracks with severity. In a Wisconsin cohort of 690 adults examined twice, four years apart, a 10% weight loss predicted a 26% decrease in the AHI, and a 10% weight gain predicted a 32% increase [JAMA 2000]. That is an observational finding, not a trial of a weight-loss drug.
Zepbound’s active ingredient, tirzepatide, is a dual GIP/GLP-1 receptor agonist. In the two sleep apnea trials, participants on tirzepatide lost an average of 17.7% and 19.6% of their body weight by week 52, compared with 1.6% and 2.3% on placebo [NEJM]. The percent change in AHI was about 51% and 59% on tirzepatide versus about 3% on placebo [NEJM].
Where CPAP Falls Short
Let’s be clear: CPAP therapy works at what it is built to do. When used, it keeps airways open, restores normal breathing patterns, and reduces snoring and daytime sleepiness. The weaker point is evidence that it prevents heart attacks and strokes. The SAVE trial assigned 2,717 adults with moderate-to-severe sleep apnea and heart or brain blood vessel disease to CPAP plus usual care or usual care alone. Over a mean of 3.7 years, a major cardiovascular event occurred in 17.0% of the CPAP group and 15.4% of the usual-care group, a difference that was not statistically significant. Average CPAP use in that trial was 3.3 hours per night [SAVE].
The other problem is adherence. A 2016 review of 82 studies covering 1994 to 2015 put the overall CPAP non-adherence rate at 34.1%, using a benchmark of 7 hours per night, and found no meaningful improvement over those 20 years [Rotenberg 2016]. Common complaints include a claustrophobic mask, noise that disturbs a partner, and the hassle of traveling with the equipment.
Sleep apnea itself is associated with major cardiovascular complications [NEJM]. For people who cannot or will not use a machine, a medicine option matters.
What This Means for Patients
For someone who has struggled with CPAP, the idea of a weekly injection that could reduce sleep apnea severity is appealing. It’s worth approaching this development with both optimism and realism.
On the hopeful side, once-weekly dosing is simpler than nightly CPAP use. There’s no equipment to clean, no mask to adjust, no machine to pack for trips. At week 52, 42% and 50% of participants on tirzepatide had remission or mild, non-symptomatic sleep apnea (an AHI under 5, or 5 to 14 with a low sleepiness score), compared with 16% and 14% on placebo. Tirzepatide also lowered systolic blood pressure and a blood marker of inflammation, though the trials were not designed to show fewer heart attacks or strokes [NEJM].
However, important caveats remain. The approval applies specifically to adults with moderate-to-severe obstructive sleep apnea who also have obesity [Zepbound label]. It may not be appropriate for every sleep apnea patient, particularly those whose condition stems from anatomical factors unrelated to weight.
Safety information
Zepbound carries a boxed warning. In rats, tirzepatide caused thyroid C-cell tumors, and it is unknown whether it causes these tumors, including medullary thyroid carcinoma, in humans. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [Zepbound label].
The most common side effects are digestive: nausea, diarrhea, vomiting, constipation, abdominal discomfort and pain, along with injection site reactions, fatigue, allergic reactions, burping, hair loss, and acid reflux. The FDA also lists warnings for pancreatitis, gallbladder problems, low blood sugar, acute kidney injury, and suicidal thoughts or behavior [FDA]. In the sleep apnea trials, diarrhea affected 26.3% and 21.8% of participants on tirzepatide versus 12.5% and 8.8% on placebo, and nausea affected 25.4% and 21.8% versus 10.0% and 5.3% [NEJM full text].
Cost and coverage are another real question. CMS lists Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity as a use that can be covered under the basic Medicare Part D benefit [CMS]. Coverage by other insurers varies, so ask your plan and pharmacy what applies to the sleep apnea indication. The trials lasted 52 weeks, so they do not show how long people need to keep taking it or what happens after stopping. That is a conversation worth having with a healthcare provider who understands both the benefits and the commitments involved.
Zepbound’s approval marks a real change for a condition long dominated by devices and surgery. For adults with obesity and moderate-to-severe sleep apnea, it adds a medicine to the options, with a boxed warning and digestive side effects to weigh. For those who’ve struggled with CPAP or felt stuck without good options, it is worth discussing with a doctor. It won’t replace every CPAP machine overnight.
Sources
- FDA - FDA approves first medication for obstructive sleep apnea, Dec 20, 2024
- FDA - Fast Track
- FDA - Priority Review
- New England Journal of Medicine - Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA), 2024
- JAMA - Longitudinal study of moderate weight change and sleep-disordered breathing, 2000
- New England Journal of Medicine - CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea (SAVE), 2016
- Journal of Otolaryngology - Head and Neck Surgery - Trends in CPAP adherence over twenty years, 2016
- Zepbound prescribing information (FDA-approved label, hosted by Eli Lilly)
- SURMOUNT-OSA full text (PubMed Central), adverse event tables
- CMS - Medicare GLP-1 Bridge, information for Part D plans
Photo by
Photo by